background
object
airway
eosinophilia
associ
increas
risk
asthma
exacerb
howev
impact
sever
exacerb
larg
unknown
describ
sputum
inflammatori
phenotyp
asthma
exacerb
correl
sever
treatment
respons
method
patient
present
hospit
asthma
exacerb
recruit
period
follow
week
induc
sputum
collect
visit
patient
underw
spirometri
arteri
blood
ga
analysi
fraction
exhal
nitric
oxid
analysi
white
blood
cell
count
screen
common
respiratori
virus
bacteria
eosinophil
exacerb
ee
defin
sputum
eosinophil
noneosinophil
exacerb
nee
result
total
patient
enrol
success
sputum
induct
baselin
sputum
eosinophil
ee
patient
ee
significantli
lower
forc
expiratori
volum
fev
predict
p
patient
nee
furthermor
ee
patient
like
requir
supplement
oxygen
admiss
vs
p
preval
respiratori
virus
ee
nee
patient
vs
p
bacteri
infect
vs
p
fraction
expiratori
nitric
oxid
feno
correl
sputum
eosinophil
p
predict
airway
eosinophilia
sensit
specif
conclus
find
suggest
eosinophil
asthma
exacerb
may
clinic
sever
nee
support
identif
higher
risk
patient
specif
intervent
asthma
chronic
inflammatori
diseas
airway
variabl
airflow
obstruct
episod
exacerb
inflammatori
phenotyp
stabl
asthmat
patient
well
describ
inflammatori
phenotyp
exacerb
much
less
examin
infect
natur
alter
cellular
composit
sputum
relationship
respiratori
pathogen
sputum
phenotyp
natur
occur
exacerb
report
asthma
patient
sputum
eosinophilia
stabl
diseas
sever
airflow
obstruct
despit
optim
treatment
frequent
exacerb
howev
remain
larg
unknown
whether
airway
inflamm
phenotyp
asthma
exacerb
associ
symptom
lung
function
eosinophil
asthma
inde
associ
frequent
also
sever
exacerb
would
highlight
need
prevent
patient
airway
eosinophilia
exacerb
asthma
lower
forc
expiratori
volum
fev
like
requir
supplement
oxygen
admiss
without
eosinophilia
suggest
eosinophil
asthma
exacerb
sever
noneosinophil
exacerb
measur
group
includ
new
therapeut
option
treatment
therefor
primari
aim
studi
evalu
whether
patient
present
airway
eosinophilia
asthma
exacerb
pronounc
bronchoconstrict
patient
without
eosinophilia
studi
conduct
bispebjerg
univers
hospit
copenhagen
denmark
patient
year
age
present
acut
asthma
emerg
depart
ed
recruit
period
begin
juli
patient
pulmonari
diseas
asthma
ie
copd
exclud
main
outcom
forc
expiratori
volum
fev
exacerb
followup
secondari
outcom
includ
marker
sever
peakflow
arteri
blood
ga
analys
etc
well
asthma
control
questionnair
acq
furthermor
want
evalu
use
fraction
expiratori
nitric
oxid
feno
blood
eosinophil
marker
eosinophil
phenotyp
acut
asthma
final
wish
determin
role
respiratori
pathogen
inflammatori
phenotyp
asthma
exacerb
particip
examin
within
h
admiss
week
research
unit
hospit
regardless
clinic
statu
admiss
patient
treat
salbutamolipratropium
given
mg
methylprednisolon
studi
approv
local
scientif
ethic
committe
protocol
nr
subject
gave
inform
consent
sputum
induc
accord
european
respiratori
societi
er
guidelin
process
describ
pavord
et
al
cell
count
obtain
nonsquam
cell
cutoff
valu
use
classifi
patient
either
eosinophil
exacerb
ee
noneosinophil
exacerb
nee
feno
analys
nioxminor
aerocrin
solna
sweden
follow
recommend
ersamerican
thorac
societi
at
use
mean
two
measur
appli
atsdefin
lower
cutoff
valu
ppb
blood
sampl
taken
ed
shortli
admiss
includ
full
white
blood
cell
differenti
count
measur
total
ige
hospit
laboratori
peakflow
peripher
satur
measur
treatment
given
arteri
blood
ga
collect
cours
initi
stabil
subject
ed
time
oxygen
administ
requir
spirometri
perform
accord
er
recommend
within
h
admiss
use
dailycalibr
jaeger
spiromet
carefus
san
diego
ca
usa
asthma
control
assess
acq
nasal
secret
collect
use
flock
swab
copan
brescia
itali
test
use
tandem
multiplex
realtim
pcr
assay
detect
comprehens
rang
respiratori
virus
human
adenoviru
speci
bd
human
bocaviru
coronavirus
influenza
virus
b
c
parainfluenzavirus
ki
wu
polyomavirus
respiratori
syncyti
viru
type
b
human
metapneumoviru
rhinovirus
detect
separ
revers
transcriptas
rt
pcr
bacteri
cultur
spontan
expector
gather
exacerb
assess
hospit
laboratori
data
analys
spss
version
ibm
armonk
new
york
usa
normal
distribut
data
report
mean
ae
sd
analys
use
student
ttest
continu
variabl
chisquar
test
categor
variabl
measur
feno
normal
distribut
log
transform
report
geometr
mean
gm
ci
cell
count
packyear
smoke
usag
inhal
corticosteroid
icss
report
median
rang
comparison
made
use
mannwhitney
test
unpair
analys
wilcoxon
signedrank
test
pair
analys
spearman
correl
assess
abil
feno
blood
eosinophil
predict
sputum
eosinophil
exacerb
multivari
logist
regress
analys
perform
correct
age
packyear
daili
dose
ic
receiv
oper
characterist
roc
curv
construct
variabl
overal
accuraci
test
measur
area
roc
curv
auc
analys
pvalu
consid
signific
studi
period
total
patient
admit
acut
asthma
ed
year
total
patient
agre
particip
main
reason
given
declin
particip
logist
come
back
followup
visit
success
sputum
induct
includ
exacerb
analys
followup
patient
drop
remain
patient
success
sputum
induct
total
patient
sputum
cell
differenti
count
visit
use
followup
analys
characterist
studi
subject
shown
tabl
time
exacerb
sputum
eosinophil
sputum
total
cell
count
neutrophil
differ
ee
nee
group
tabl
spirometri
revers
done
admiss
agonist
could
withheld
patient
requir
time
admiss
spirometri
differ
ee
ae
h
p
nee
patient
ae
h
time
sinc
last
dose
agonist
lower
ee
group
ae
h
p
nee
group
ae
h
despit
fev
significantli
lower
patient
ee
patient
nee
vs
p
remain
signific
adjust
smoke
ic
use
furthermor
revers
higher
patient
ee
compar
nee
vs
p
spite
patient
receiv
bronchodil
treatment
ed
tabl
peakflow
arriv
show
trend
toward
lower
level
ee
patient
p
tabl
oxygen
satur
lower
ee
patient
vs
p
nee
patient
tabl
arteri
blood
gase
drawn
stabil
treatment
therefor
nee
patient
ee
patient
given
supplement
oxygen
lmin
time
ns
patient
ee
lower
arteri
ph
vs
p
po
pco
differ
group
admiss
supplement
oxygen
administ
satur
drop
happen
frequent
patient
ee
p
patient
nee
tabl
eight
patient
discharg
ed
remain
patient
admit
three
night
exacerb
patient
use
ic
follow
exacerb
patient
prescrib
ic
respiratori
viru
detect
patient
time
exacerb
rhinoviru
human
coronaviru
preval
detect
respiratori
virus
ee
p
nee
patient
furthermor
percentag
eosinophil
neutrophil
similar
patient
without
viral
infect
p
respect
thirtysix
patient
abl
produc
spontan
sputum
bacteri
cultur
six
patient
posit
cultur
either
haemophilu
influenza
n
serratia
marcescen
n
staphylococcu
aureu
n
streptococcu
pneumonia
n
preval
bacteri
infect
differ
group
ee
vs
nee
p
exclud
patient
bacteri
infect
chang
conclus
studi
exacerb
patient
ee
group
patient
nee
group
prescrib
mg
oral
prednisolon
taken
daili
day
ns
followup
seven
ee
patient
four
nee
patient
sputum
eosinophil
patient
readmit
revisit
gp
observ
period
followup
nee
patient
poorer
asthma
control
ee
patient
acq
score
vs
p
despit
similar
ic
dose
tabl
exacerb
followup
fev
improv
ee
ae
ae
p
nee
group
ae
ae
p
followup
fev
similar
two
group
p
ee
nee
group
total
blood
leucocyt
decreas
exacerb
followup
ee
cellsl
p
nee
cellsl
p
driven
decreas
neutrophil
ee
cellsl
p
nee
cellsl
p
blood
eosinophil
chang
ee
cellsl
p
nee
cellsl
p
feno
highest
ee
patient
ppb
ci
vs
ppb
ci
p
tabl
feno
correl
sputum
eosinophil
p
multivari
logist
regress
analysi
reveal
feno
predict
presenc
sputum
eosinophilia
model
correct
age
packyear
smoke
dose
ic
r
p
roc
curv
feno
predict
ee
auc
ci
p
whole
popul
use
cutoff
valu
ppb
sensit
specif
detect
ee
exacerb
patient
feno
ppb
lower
fev
ae
p
patient
feno
ppb
ae
blood
eosinophil
also
correl
sputum
eosinophil
p
less
predict
feno
sputum
eosinophilia
r
p
adjust
confound
describ
roc
curv
blood
eosinophil
predict
ee
auc
ci
p
feno
blood
eosinophil
show
similar
predict
abil
followup
visit
data
shown
studi
demonstr
eosinophil
airway
inflamm
acut
asthma
exacerb
associ
lower
fev
measur
within
h
admiss
hospit
higher
requir
oxygen
supplement
furthermor
signific
proport
patient
airway
eosinophilia
time
exacerb
continu
elev
airway
eosinophil
followup
despit
treat
system
steroid
find
suggest
eosinophil
asthma
exacerb
may
clinic
sever
nee
eosinophil
inflamm
may
persist
despit
standard
antiinflammatori
treatment
pronounc
bronchoconstrict
patient
sputum
eosinophilia
exacerb
compar
without
describ
turner
et
al
fev
vs
p
similar
studi
di
franco
et
al
show
increas
fev
exacerb
recoveri
correl
decreas
sputum
eosinophil
unstabl
patient
followup
still
high
sputum
eosinophil
despit
treatment
peripher
oxygen
satur
arteri
ph
within
normal
rang
patient
group
slightli
lower
ee
group
patient
like
requir
supplement
oxygen
admiss
hospit
admiss
howev
respir
frequenc
differ
group
neither
partial
pressur
oxygen
carbon
dioxid
eosinophil
airway
inflamm
associ
pronounc
airway
smooth
muscl
hypertrophi
sever
asthma
gener
known
associ
pronounc
structur
chang
peripher
airway
studi
fatal
nearfat
asthma
indic
increas
inflamm
exacerb
aggrav
chronic
state
caus
pronounc
mucu
oedema
lumen
occlus
mucu
plug
set
predominantli
eosinophil
infiltr
light
even
subtl
chang
oxygen
could
repres
differ
patholog
involv
prove
prognost
valu
studi
requir
investig
one
main
limit
studi
sampl
size
prohibit
elabor
subgroup
analys
rel
low
particip
rate
risk
introduc
select
bia
howev
reason
given
want
particip
studi
relat
asthma
sever
unlik
specif
patient
certain
sputum
inflammatori
phenotyp
sever
studi
shown
fev
improv
upon
initi
treatment
hospit
fulli
recov
preexacerb
level
day
even
patient
receiv
appropri
treatment
therefor
measur
fev
within
h
admiss
commonli
use
studi
acut
asthma
use
previou
studi
acut
asthma
acknowledg
measur
fev
admiss
reflect
interact
sever
respons
initi
treatment
howev
subset
patient
document
pef
arriv
highli
correl
subsequ
fev
strength
studi
sputum
collect
togeth
clinic
inform
inflammatori
marker
sampl
detect
respiratori
pathogen
exacerb
recoveri
heterogen
reallif
popul
eosinophil
airway
inflamm
stabl
diseas
predictor
steroid
respons
adjust
treatment
base
sputum
cell
count
reduc
frequenc
sever
exacerb
without
increas
overal
ic
dose
studi
acq
followup
highest
noneosinophil
patient
despit
similar
fev
group
could
indic
treatment
respons
least
regard
symptom
follow
exacerb
also
lower
noneosinophil
group
could
also
symptom
wheez
eg
cough
captur
acq
spirometri
promin
noneosinophil
patient
studi
feno
blood
eosinophil
abl
predict
sputum
eosinophil
exacerb
correl
similar
previou
studi
stabl
asthma
larg
proport
patient
persist
eosinophilia
followup
could
due
insuffici
treatment
five
patient
medium
high
dose
ic
patient
eosinophilia
followup
could
repres
underli
phenotyp
increas
risk
futur
exacerb
howev
clarifi
case
eosinophilia
result
prolong
respons
exacerb
requir
studi
assess
inflammatori
profil
stabl
phase
subsequ
exacerb
activ
eosinophil
thought
play
direct
role
tissu
remodel
reduc
rate
exacerb
upward
select
asthmat
patient
substanti
eosinophilia
frequent
exacerb
treatment
might
also
attenu
exacerb
sever
patient
predominantli
eosinophil
inflammatori
responsein
studi
patient
howev
remain
explor
conclus
fev
admiss
significantli
lower
patient
sputum
eosinophilia
acut
exacerb
compar
patient
noneosinophil
inflamm
find
add
limit
data
avail
eosinophilia
acut
asthma
suggest
new
biolog
treatment
option
becom
avail
may
attenu
effect
exacerb
whether
evalu
presenc
airway
eosinophilia
exacerb
either
directli
use
biomark
feno
prove
use
clinic
set
evalu
larger
multicentr
trial
